Study of ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
Advanced Solid Tumors Harboring NTRK Fusion|Primary Central Nervous System Tumors Harboring NTRK Fusion
DRUG: ICP-723
Objective response rate (ORR), The objective response rate (ORR) evaluated by the Independent Center Review, Through study completion, an average of 4 years
ORR assessed by the investigator, Through study completion, an average of 4 years|DCR as assessed by the investigator and the IRC, Through study completion, an average of 4 years|Time to response (TTR) as assessed by the investigator and the IRC, Through study completion, an average of 4 years|Duration of response (DOR) as assessed by the investigator and the IRC, Through study completion, an average of 4 years|Progression-free survival (PFS) as assessed by the investigator and the IRC, Through study completion, an average of 4 years|Intracranial objective response rate (IC-ORR) as assessed by the investigator and IRC, Through study completion, an average of 4 years|central nervous system progression-free survival (CNS-PFS) as assessed by the investigator and IRC, Through study completion, an average of 4 years|Overall survival (OS), Through study completion, an average of 4 years|The incidence, character and severity of adverse events as assessed per NCI-CTCAE v5.0 criteria, Through study completion, an average of 4 years|The maximum plasma concentration observed (Cmax), Through study completion, an average of 4 years|Time of maximum observed plasma concentration (Tmax), Through study completion, an average of 4 years|Elimination half-life (t1/2), Through study completion, an average of 4 years|AUC0-âˆž, Through study completion, an average of 4 years|AUC0-t, Through study completion, an average of 4 years|Apparent clearance (CL/F), Through study completion, an average of 4 years|Apparent volume of distribution (Vz/F), Through study completion, an average of 4 years
Colony-stimulating factor (CSF) concentrations, Through study completion, an average of 4 years
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors